Dandan Xu

机构：Shanghai Public Health Clinical Center, First Affiliated Hospital of Xinxiang Medical University, Heilongjiang Provincial Hospital, Henan Medical University, Nanjing Medical University · ORCID：0000-0003-2798-8349

发表论文 133 篇 · 总被引 2981 次 · h-index 26

代表论文

• Lipogenic enzyme FASN promotes mutant p53 accumulation and gain-of-function through palmitoylation (2025 · Nature Communications · 被引 26)
• Associations of Serum Per- and Polyfluoroalkyl Substances with Genotoxic Biomarkers: New Insights from Cross-Sectional and In Vivo Evidence (2025 · Environmental Science & Technology · 被引 12)
• Macrophages exploit the mannose receptor and JAK-STAT1-MHC-II pathway to drive antigen presentation and the antimycobacterial immune response after BCG vaccination (2024 · Acta Biochimica et Biophysica Sinica · 被引 9)
• Combination of arsenic trioxide and apatinib synergistically inhibits small cell lung cancer by down-regulating VEGFR2/mTOR and Akt/c-Myc signaling pathway via GRB10 (2024 · Hereditas · 被引 6)
• Per- and polyfluoroalkyl substances and platelet-related hematotoxicity: An integrated study of in silico, toxicological, and population evidence (2025 · Journal of Hazardous Materials · 被引 4)
• Efficacy and safety of SHEN26, a novel oral small molecular RdRp inhibitor for COVID-19 treatment: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial (2025 · Virology Journal · 被引 4)